Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, ...

A majority of patients with obstructive hypertrophic cardiomyopathy (HCM)—a condition that results in excess thickening of the heart muscle—who were candidates for a procedure to relieve the ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten (Bristol Myers Squibb) also improved symptoms, biomarker levels and quality of life metrics compared ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. The Food and Drug Administration (FDA) has approved Camzyos ™ (mavacamten) for the treatment of adults with ...